While vaccines remain the best strategy to prevent COVID-19, mAbs could potentially benefit certain vulnerable populations before or after exposure to SARS-CoV-2, such as the unvaccinated or recently vaccinated high-risk patients.
MIT License
1
stars
4
forks
source link
solve discrepancy and add new excl crit to flowchart #55
table_elig_treat_redacted2.csv
not excluding people not in a high risk group.table_non_elig_flowchart_redacted.csv
.